Taking into account the reports of elevated IL-6 and TNF-α levels in BD patients, it is conceivable that therapeutic interventions that downregulate these cytokine plasma and brain levels in BD patients would, in turn, exhibit therapeutic benefits. This evidence concerns the gene TNF and Behcet disease.